Research

Progress with new Alzheimer’s drug lecanemab announced by manufacturers Eisai and Biogen

Yesterday (27 September 2022), Eisai Co. Ltd. and Biogen announced top-line results for a major trial on the drug lecanemab in slowing down the progress of Alzheimer’s disease. Alzheimer's Society comments on this Alzheimer’s progression drug hope.

PM announces dementia mission in memory of Dame Barbara Windsor

Today the Prime Minister Boris Johnson announced that he will be launching a new ‘national dementia mission’ in honour of the late Dame Barbara Windsor.

Real stories

Researching the antiviral immune system’s role in Alzheimer’s disease

29 July 2022

£7.5 million collaboration with NIHR to fund early career researchers in dementia

Alzheimer’s Society and NIHR announce a £7.5 million partnership to provide 45 brand new post-doctoral positions in dementia for NIHR Applied Research Collaborations.

Meet the researchers from our Dementia Research Leaders programme

Learn about the researchers who are part of our Dementia Research Leaders programme, which supports early career researchers from biomedical, clinical and social science backgrounds.

Our Research Mission Statement

Learn about Alzheimer's Society's new direction of travel for dementia research from 2022 to 2027.

Real stories

Researching inequities in dementia care

01 June 2022

Real stories

Researching the role of the thalamus and how tau proteins spread in Alzheimer’s

31 March 2022

IMPACT Research Fund

Thank you for being part of the future of dementia research. Your support will help scientists push forwards towards the discoveries that all of us in the dementia community have been waiting for.